Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms.
Maeda A, Irie K, Ando H, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Aoki M, Inaguma K, Kajita M, Fujimura A, Fukushima S.
Maeda A, et al. Among authors: irie k.
Cancer Chemother Pharmacol. 2019 Jan;83(1):107-113. doi: 10.1007/s00280-018-3710-9. Epub 2018 Oct 27.
Cancer Chemother Pharmacol. 2019.
PMID: 30368586